These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26358784)

  • 41. Prediction of Promiscuity Cliffs Using Machine Learning.
    Blaschke T; Feldmann C; Bajorath J
    Mol Inform; 2021 Jan; 40(1):e2000196. PubMed ID: 32881355
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Monitoring global growth of activity cliff information over time and assessing activity cliff frequencies and distributions.
    Stumpfe D; Bajorath J
    Future Med Chem; 2015 Aug; 7(12):1565-79. PubMed ID: 26334207
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Exploring SAR continuity in the vicinity of activity cliffs.
    Namasivayam V; Iyer P; Bajorath J
    Chem Biol Drug Des; 2012 Jan; 79(1):22-9. PubMed ID: 21985661
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Many drugs contain unique scaffolds with varying structural relationships to scaffolds of currently available bioactive compounds.
    Hu Y; Bajorath J
    Eur J Med Chem; 2014 Apr; 76():427-34. PubMed ID: 24602788
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Activity cliffs: facts or artifacts?
    Medina-Franco JL
    Chem Biol Drug Des; 2013 May; 81(5):553-6. PubMed ID: 23375049
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systematic analysis of public domain compound potency data identifies selective molecular scaffolds across druggable target families.
    Hu Y; Wassermann AM; Lounkine E; Bajorath J
    J Med Chem; 2010 Jan; 53(2):752-8. PubMed ID: 20000355
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systematic Exploration of Activity Cliffs Containing Privileged Substructures.
    Hu H; Bajorath J
    Mol Pharm; 2020 Mar; 17(3):979-989. PubMed ID: 31978299
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Advances in Activity Cliff Research.
    Dimova D; Bajorath J
    Mol Inform; 2016 May; 35(5):181-91. PubMed ID: 27492084
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Activity cliffs in PubChem confirmatory bioassays taking inactive compounds into account.
    Hu Y; Maggiora GM; Bajorath J
    J Comput Aided Mol Des; 2013 Feb; 27(2):115-24. PubMed ID: 23296990
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bioactivity landscape modeling: chemoinformatic characterization of structure-activity relationships of compounds tested across multiple targets.
    Waddell J; Medina-Franco JL
    Bioorg Med Chem; 2012 Sep; 20(18):5443-52. PubMed ID: 22178187
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Computational analysis of multi-target structure-activity relationships to derive preference orders for chemical modifications toward target selectivity.
    Wassermann AM; Peltason L; Bajorath J
    ChemMedChem; 2010 Jun; 5(6):847-58. PubMed ID: 20414918
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Advancing the activity cliff concept.
    Hu Y; Stumpfe D; Bajorath J
    F1000Res; 2013; 2():199. PubMed ID: 24555097
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systematic identification of target set-dependent activity cliffs.
    Hu H; Stumpfe D; Bajorath J
    Future Sci OA; 2019 Feb; 5(2):FSO363. PubMed ID: 30828462
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Data-Driven Exploration of Selectivity and Off-Target Activities of Designated Chemical Probes.
    Miljković F; Bajorath J
    Molecules; 2018 Sep; 23(10):. PubMed ID: 30249057
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structural interpretation of activity cliffs revealed by systematic analysis of structure-activity relationships in analog series.
    Sisay MT; Peltason L; Bajorath J
    J Chem Inf Model; 2009 Oct; 49(10):2179-89. PubMed ID: 19761254
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Data set of activity cliffs with single-atom modification and associated X-ray structure information for medicinal and computational chemistry applications.
    Hu H; Bajorath J
    Data Brief; 2020 Dec; 33():106364. PubMed ID: 33088875
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Introducing a new category of activity cliffs with chemical modifications at multiple sites and rationalizing contributions of individual substitutions.
    Stumpfe D; Hu H; Bajorath J
    Bioorg Med Chem; 2019 Aug; 27(16):3605-3612. PubMed ID: 31272836
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Many approved drugs have bioactive analogs with different target annotations.
    Hu Y; Lounkine E; Bajorath J
    AAPS J; 2014 Jul; 16(4):847-59. PubMed ID: 24871342
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Methods for computer-aided chemical biology. Part 2: Evaluation of compound selectivity using 2D molecular fingerprints.
    Vogt I; Stumpfe D; Ahmed HE; Bajorath J
    Chem Biol Drug Des; 2007 Sep; 70(3):195-205. PubMed ID: 17718714
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Composition and topology of activity cliff clusters formed by bioactive compounds.
    Stumpfe D; Dimova D; Bajorath J
    J Chem Inf Model; 2014 Feb; 54(2):451-61. PubMed ID: 24437577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.